Fast forward to now, & we’re firing on all cylinders - A+ team, home in Fenway, advancing platform & programs. Thx & welcome to our newest partners on this journey - @GoogleVentures ARCH Venture @SixthStreetNews@DCVC@Mubadala! Can’t wait to see what this next phase brings!
5/5
Our annual survey of the best #NBTAcademicStartups in 2021 continues with @chromamedicine and @tunetx_news, two companies using epigenome editing for precision medicine https://t.co/871umTUHjg
@JohnDoench In my experience gRNA expression from a DNA template can vary widely (10 fold or greater) and is often the culprit of “good vs bad” in this context. Please, everyone, measure measure measure before you make conclusions.
Coming up next week, Morgan Maeder, PhD, Senior Director of Payload Sciences at Chroma, will present her research at #ASGCT22 as an Outstanding New Investigator award recipient. Don’t miss out - register here: https://t.co/QkkDHnRILk #EpigeneticEditing#GeneTherapy#Epigenetics
“The company hasn’t been as crisp on execution as it just needs to be, should be, has to be,” Mullen said of the leadership transition.
Perhaps they need to be CRISPR?
https://t.co/zEjED5pcKc
Respectfully:
1. There is no "CRISPR throne."
2. There is no battle.
3. The zero-sum-game-ism is not helpful.
Genomic therapies are REALLY hard to get to work, in the editing space everyone is relatively early, the target space is large, and there is room for many.